An Open-label Phase 1/2a Study of BAL101553 Administered as Intravenous 48-hour Infusions in Adult Patients With Advanced Solid Tumors
Phase of Trial: Phase I/II
Latest Information Update: 03 Jan 2018
At a glance
- Drugs Lisavanbulin (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Basilea Pharmaceutica
- 03 Jan 2018 According to a Basilea Pharmaceutica media release, recruitment in phase 1 part of the study has been completed. Also, company plans to present phase 1 results at upcoming scientific conferences.
- 10 Aug 2017 Completion of patient recruitment into this trial is expected in the first half of 2018 according to a Basilea Pharmaceutica media release.
- 06 Jun 2017 According to a Basilea Pharmaceuticals media release, the company expected completion of dose-escalation towards the end of 2017.